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Snake bite is a significant public health problem in rural areas of many parts of the world1. 
Venomous snakes are found worldwide, except for a few islands and the frozen environments. Snake 
bite most commonly affects those living in the tropical and sub-tropical areas of Africa, Asia, the 
Americas and Oceania. The morbidity and mortality resulting from bites are significant. Huge 
variation in management, coupled with many patients’ traditional cultural beliefs and lack of 
resources contribute to a huge disease burden from snake bites
2
. The World Health Organisation 
(WHO) recently recognised snake bite as a neglected tropical disease and this has led to a global 
snake bite initiative to improve clinical outcome following snake bites3. 
 
The aim of this paper is to review current literature on the incidence, pathophysiology and 
management of snake bite. The aim is to help clinicians to a better understanding of the 
management of bites, especially when in situations with minimal resources and lack of anti-venom, 
which is where most snake bites occur. This review discusses a safe approach to clinical management 
in a field with limited evidence. A treatment guide to use of anti-venom is included to facilitate rapid 
decision making in stressful clinical situations. 
 
Surgeons in rural hospitals in low and middle income countries are often involved in the 
management of snake bite patients due to the nature of tissue damage caused by venom or wrong 
primary management, or because surgeons might be amongst the more senior staff available to help 
manage critically ill patients in such district hospitals. Most surgeons are outside their comfort zone, 
however, when they have to manage a snake bite patient, and this paper attempts to provide a 
structured approach to management. 
Burden of Disease 
Snake bite has recently been recognised by the World Health Organisation as a neglected tropical 
disease1. An exact estimation of the incidence of snake bite has not yet been achieved and remains an 
epidemiological challenge2,4 . Estimates vary greatly and no accurate morbidity and mortality data exist. 
Swaroop and Grabb5 first attempted to quantify the global burden of snakebite but admitted that their 
data was flawed. Their study suggested that the global annual mortality from snakebite is between 30 
000 and 40 000. This was calculated mostly from hospital data and the authors recognised the gross 
inaccuracy from these results since most bites go unreported or take place in regions where data is not 
accurately collected5.  
 
More recent attempts to determine the annual global deaths from snake bite vary between 20 000 and 
125 0001,6,7. Estimates are that the number of bites may be around 5 million per year with more than 2.5 
million envenomings6,7. The highest incidences appear to be in Latin America, sub-Saharan Africa, 
South and South-East Asia6,7. Interestingly, mortality rates were less in Latin American countries than 
Africa and Asia with similar incidences of bites7. The reason for this is unclear, but has been suggested 
to be due to increased availability and better developed local anti-venom, or better local guidelines on 
management of bites7.  
 
There remains very little evidence detailing the extent of morbidity, long term disability and major 
psychological impact from snakebite. This is of particular importance since many victims are 
agricultural workers and a return to work will likely provide significant psychological stress. Disability 
may also hamper the victim’s functional ability to work. 
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 Some studies suggest permanent disfigurement or disability in 18-19% of victims8,9. This is mostly due 
to local tissue necrosis resulting in debridement, amputation or permanent scarring. Hypoxic brain 
injury secondary to neurotoxic bites or haemorrhagic complications from envenoming are also causes 
of long term disability2. Significant renal injury can lead to dependence on dialysis following 
envenoming and is common after bites from Russell’s viper in South Asia10. Permanent disability and 
disfigurement is of particular concern to the majority of snakebite victims, since most bites occur in 
regions with poor access to healthcare or income support such as Sub-Saharan Africa and South East 
Asia7. 
Pathophysiology 
Bites occur most commonly on the lower extremity as a result of accidentally stepping close to the 
snake11. This is particularly so in low and middle income countries where victims use rural footpaths, 
often at night. In regions where it is customary to sleep on the ground or on low beds, bites occur at 
night as cold blooded snakes search for a warm environment. There has been growing reports of exotic 
venomous snake bites in the Western world due to increasing numbers being kept as pets. Here victims 
are often bitten on the upper extremity when attempting to handle the snake, often while intoxicated11. 
 
Most venomous bites occur from species with anteriorly located fangs, such as the Viperidae and 
Elapidae species. Envenoming from posterior fanged snakes is rare, yet can be highly dangerous, as 
with bites from species such as the boomslang (Dispholidus typus). Snake venoms are complex 
collections of peptides, enzymes and other toxins that vary greatly even amongst sub-species2,11.  This 
allows the venom to induce several systemic responses in potential prey. The most clinically significant 
toxins are those that cause tissue necrosis and adversely affect the neurological, cardiovascular and 
coagulation systems2. 
 
Snake venoms contain multiple compounds that cause systemic effects. These vary from neurotoxic 
pre- and post synaptic blockers, to cytotoxic compounds such as Phospholipase A2 that cause severe 
local necrosis2,12,13. The toxicology of snake venom is complex and there remains great heterogeneity 
amongst species, making development of anti-venom difficult and challenging14.  
 
Probably the most common clinical effect of snake bite is tissue necrosis that can cause extensive soft 
tissue destruction. Envenoming by a wide range of species, particularly the Viperidae such as the puff-
adder and rattlesnake species are responsible for tissue necrosis through cytotoxic compounds. Cell 
lysis, increased vascular permeability and thrombosis within the micro-circulation lead to cell death, 
severe local inflammation and ischaemia2,12. The systemic inflammatory response syndrome is triggered 
to varying degree and can result in severe local and systemic sepsis. Debridement is often required2,11,12. 
Compartment syndrome and the requirement for fasciotomy are not as common as previously thought, 
and can be prevented by good medical management15. Snake bite induced nephropathy is a common 
sequel to cytotoxic envenoming leading to acute renal failure12. Rhabdomyolysis, cardio-vascular 
compromise, changes within the micro-circulation and coagulopathy all contribute to nephropathy12. 
Pathological changes that can be seen in the kidney include acute tubular necrosis, glomerulonephritis 
and vasculitis, producing a range of clinical manifestations12. 
 
Snake venom is thought to cause neurotoxicity exclusively by affecting the peripheral nervous system 
with almost no penetrance into the central nervous system2,16. Toxicology is complex, affecting both 
pre- and post-synaptic receptors. The clinical effects vary greatly, with the most feared that of 
respiratory depression and neurogenic shock2. In certain species such as the black mamba (Dendroaspis 
polylepis), symptoms of neurotoxicity start with metallic taste, ptosis and gradual bulbar paralysis2,15 . 
These patients carry a high risk of death and should be treated with great urgency (see management 
section). 
 
Patients with significant envenoming can have profound cardio-vascular compromise leading to a 
variety of clinical manifestations with multi-factorial causes. Increased vascular permeability and 
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dilatation is thought to be implicated, and may be due to the release of cytokines such as bradykinin2,17. 
Cardiogenic shock is seen in severe bites secondary to cardiac specific myotoxic compounds and 
venom induced conduction defects. This can be further complicated by ischaemia secondary to 
coronary artery thrombosis secondary to coagulopathy18. 
 
Snake bite induced coagulopathy is a complex and diverse clinical problem. It is responsible for a large 
proportion of snake bite mortality and can be lethal due to complex pathophysiology which is often 
only reversed with anti-venom13,15. Venom heterogeneity results in disruption of the coagulation 
pathway at various stages. A range of haemostatic disturbances can be seen due to vessel damage due to 
cytokines and trauma, reduced coagulability, disseminated intravascular coagulation and the 
development of pro-thrombotic states 13. Disintegrins, lectins and phospholipases are examples of 
substances that are thought to inhibit haemostasis2,13. In some species snake venom contain pro-
coagulant factors, such as factor V, X, XIII and pro-thrombin activators resulting in a pro-thrombotic 
state2,13.  Platelet aggregation can be either inhibited or induced depending on the venom sub-type. 
Laboratory results of patients are often dramatically deranged without correlating clinical 
manifestation13. It is important that snake bite coagulopathy is managed differently to the more common 




The management of venomous snake bite remains a challenge for even the experienced clinician. Lack 
of emergency transport and rural location of most bites result in patients often presenting late after the 
clinical effects of envenoming is well established2, 19. The cultural beliefs of many rural populations 
further exacerbate the problem with traditional healers often attempting to manage the bite using 
traditional methods 2, 8. Poor education amongst rural populations and healthcare professionals alike 
result in poor first aid measures that often worsen the effects of envenoming 8, 19. Some studies in Africa 
have suggested that late presentation is not associated with worse outcome 4, 8. These conclusions can be 
challenged: with neurotoxic bites late presentation can result in respiratory failure and hypoxic death 
while haemotoxic envenoming can lead to fatal coagulopathy if untreated. 
 
A major obstacle in snake bite treatment is the correct identification of the responsible snake. Snake 
bite species vary greatly from one geographic region to another, even within countries. This makes 
developing a national or regional treatment strategy problematic. In 40% of cases the patient does not 
identify the snake and mistaking for a different species is common15, 20. Even expert herpetologists can 
misidentify the snake, resulting in inappropriate treatment with anti-venom2, 20. Attempting to kill or 
capture the snake that caused the bite further endangers the individual attempting this, as well as being 
detrimental to the local eco-system. Capturing the snake responsible for identification should therefore 
be discouraged. 
 
The difficulties facing clinicians treating snake bite is further exacerbated by the lack of availability of 
anti-venom and modern medical equipment. Most bites occur in the rural tropics and sub-tropics in low 
and middle income countries where access to health care is difficult and resources are limited7. 
Clinicians often face treating patients with advanced stages of envenoming without anti-venom. A 
systematic approach to managing the clinical syndromes resulting from snake bite is an effective and 
safe strategy for clinicians even with limited resources15, 20. 
First Aid 
Suggestions for initial treatment of snake bite vary greatly 2, 15. Most important are to avoid the use of a 
tourniquet and transport the patient to medical care as soon as possible 2, 15. Attempts to clean or incise 
the wound and to suck out any venom are ineffective and should be discouraged15. The Sutherland 
technique of pressure immobilisation involves compression bandaging of the affected limb along a 
splinted support 21. This has been widely taught to reduce venom transport but there is no evidence that 
 ISSN 2073-9990   East Cent. Afr. J. surg 
 
 
48  COSECSA/ASEA Publication    -East and Central African Journal of Surgery.  November/December 2013 Vol. 18 (3)      
 
 
this is indeed successful 10, 15, 22, 23. It may be effective in treatment of bites in which the venom is 
mainly transported via the lymphatics 15. Direct pressure pad application, on the other hand, has been 
shown to reduce venom uptake in experimental settings, although the evidence for the clinical benefit of 
this technique is limited 10, 23. Educating health care professionals and first aiders in these techniques is 
fraud with difficulty and inaccuracy; patients are more likely to be harmed by over-tight bandaging 
resulting in a tourniquet effect 15, 23. Tourniquets should be discouraged for use in immediate care 
except for bites with neurotoxic venom (e.g. mamba species) that are confidently identified; tourniquets 
should be removed within 90 minutes of application 15, 24, 25. Tourniquet use as a first aid measure is 
associated with increased hospital stay and worse outcome 8. The ischaemic effects of tourniquet use 
can greatly increase the tissue damage resulting from cytotoxic envenoming which accounts for 90% of 
bites in Africa 15.  
 
All patients that suffer venomous snake bite should be resuscitated as per Advanced Trauma Life 
Support (ATLS®) guidelines 26. The most rapid threat to life is with neurotoxic bites in which 
respiratory depression secondary to muscle paralysis is a frequent cause of mortality2, 15. The airway 
must be secured while ensuring adequate oxygenation. Patients may become hypotensive due to direct 
neurotoxicity, cardiogenic shock, bleeding or sepsis. Shock must be urgently treated with IV fluid 
therapy with appropriate monitoring. Avoiding hypoglycaemia and hypothermia are important 
resuscitative adjunct measures prior to definitive treatment. All patients should receive tetanus 
vaccination. 
Syndromic Management 
The shortage of anti-venom globally, particularly in the rural tropics, provides a major challenge to 
snakebite management. Management of the specific clinical syndrome caused by envenoming can be 
effective, whether anti-venom is available or not 15,20. As described previously, snake venom produces 
different clinical syndromes depending on the venom constituents and varies greatly 14, 15.  
Local Necrosis / Painful Progressive swelling 
Bites from Viperidae (e.g. puff-adder, diamondback rattlesnake) and some Elapidae (e.g. kraits, cape 
cobra) species are associated with severe cytotoxic effects 14, 15. This is the most common presentation 
associated with snake bite in many parts of the world, particularly Africa. The cytotoxic effects of the 
venom progress rapidly and may be severe in patients presenting late. Due to local tissue necrosis and 
the chemical nature of cytotoxic venom, the administration of anti-venom can be fairly ineffective once 
tissue damage has occurred 14. Clinical management of these bites can be very effective dealt with in a 
systematic fashion 15. 
 
Patients presenting with progressive tissue necrosis should be resuscitated as stated above. It is worth 
keeping in mind that some snakes such as the African spitting cobras can have neuro- and cytotoxic 
venom and progressive paralysis is a greater initial threat to life 15.  
 
The affected limb should be elevated and patients should receive adequate analgesia. Fluid resuscitation 
is an important aspect of management. The cytotoxic effects of the venom can cause fluid loss and 
patients are at risk of acute kidney injury from processes causing myoglobinuria 14. The affected limb 
should be monitored closely for tissue necrosis. If debridement is required, it is recommended that this 
is performed 5-7 days after the bite 15. This allows adequate demarcation margins to develop and can 
avoid unnecessary returns to the operating theatre in an unstable patient. Anti-biotic therapy is only 
indicated if signs of sepsis are present.  
 
Complications of cytotoxic envenoming include compartment syndrome, rhabdomyolysis, 
myoglobinuria and acute renal failure. Compartment syndrome is uncommon and should be managed 
with fasciotomy, if required on clinical grounds 15. Femoral vessel entrapment by the inguinal ligament 
can occur rarely, resulting in an ischaemic lower limb 27. Carpal tunnel syndrome from bites to the 
upper limb usually recovers with elevation and analgesia 15. 
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Not all patients suffering from cytotoxic bites require anti-venom. The indications include compartment 
syndrome or serious associated complications such as coagulopathy or adult respiratory distress 
syndrome (Table 1). This is required in less than 10% of cytotoxic bites 15. 
Table 1 
Indications for Anti-Venom 
 
Always use anti-venom with appropriate medical staff and monitoring available. Treat reactions 





• Swelling affecting airway 
• Bulbar paralysis affecting breathing / swallowing 
• Respiratory distress (ARDS) after cytotoxic bite 
 
Circulation 
• All confirmed envenoming from species with haematoxic venom e.g. boomslang 
• Systemic bleeding 
• Signs of intra-cerebral bleeding 
• Significant deranged clotting measurements eg APTT/PT, TEG 
• Shock not responsive to fluid therapy 
• Cardiac arrhythmias 
 
Disability 
• Triad of Pins and needles, profuse sweating and excessive salivation with metallic taste 
[suggest severe neurotoxic envenomation] 
• Evidence of severe/progressive neurotoxicity (low threshold in species known for neurotoxicity 
such as black mamba) 
• Seizures / reduced conscious level / severe headache [suggesting intra-cerebral haemorrhage] 
• Severe local swelling 
 More than ½ of limb within 24 hours 
 Significant swelling involving digits 
 Rapid extension within few hours 
 Compartment syndrome / vessel entrapment 
 
Repeating Anti-Venom 
• Continued bleeding 1-2 hours after initiating anti-venom 
• Deteriorating neurological function after 1-2hours 
• Continued coagulopathy as per laboratory measurements after 6 hours 
 
Progressive Paralysis 
Neurotoxic envenoming can cause rapid deterioration and death. This is commonly caused by Elapidae 
such as the black mamba in southern Africa and cobra species 14, 15, 20. Some patients may have minor 
local tissue damage or they may have severe necrosis and associated coagulopathy. 
 
In neurotoxic envenoming the application of an arterial tourniquet is indicated whilst awaiting hospital 
transfer, as the initial risk to life is much greater from neurotoxicity than tissue necrosis 15. Initial 
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management of neurotoxic envenoming is appropriate resuscitation with primary attention to Airway 
and Breathing. This is crucial in order to prevent respiratory failure secondary to bulbar and respiratory 
paralysis. Patients with severe envenoming will require intubation and full respiratory support and this 
should not be delayed if indicated during primary survey. Muscle-relaxants should be avoided, unless 
absolutely required for initial intubation 15. 
 
These patients require anti-venom in almost all cases. Lack of information regarding the snake 
responsible should not delay anti-venom administration if clinical signs and symptoms are highly 
suggestive of neurotoxicity. This includes difficulty in swallowing, peri-oral paraesthesiae, metallic 
taste, excessive salivation and respiratory failure. If patients are supporting their own respiratory 
function but a rapid onset generalised weakness occur, then anti-venom administration is required to 
prevent respiratory complications 15. Early intubation should be considered as this allows respiratory 
support prior to inevitable respiratory failure. Unlike in cytotoxic envenoming, anti-venom is very 
successful in reversing synaptic neurotoxicity 14, 24. If patients are ventilated and anti-venom 
administrated then recovery can be excellent, unless the venom also had significant cytotoxic or 
coagulopathic effects. 
Coagulopathy 
Coagulopathy can be the primary venomous effect of some bites, or in conjunction with neurotoxic or 
cytotoxic venom. The coagulopathic effects vary greatly depending on the venom and the 
haematological interference it produces. It is worth remembering that even if the coagulopathic effects 
of venom can produce extremely abnormal laboratory results, these do not always transpire into clinical 
morbidity or mortality. Most snake bite coagulopathy result in haemorrhagic tendency, but can rarely 
result in pro-thrombotic events and overall is a major source of snakebite mortality globally, causing as 
many as 50% of deaths 13. 
 
 As discussed previously, underlying mechanisms of coagulopathy vary greatly. Unlike other more 
common clinical causes of coagulopathy, those resulting from snake bite are not successfully treated 
using standard treatment strategies. The only successful treatment is administration of anti-venom. The 
indications for anti-venom include persistent bleeding from minor skin wounds, clinical evidence of 
intra-cranial haemorrhage, systemic bleeding or significantly deranged laboratory measurements of 
coagulation13, 15. Patients may require repeated administration of anti-venom depending on clinical 
response. Blood coagulation profiles should be rechecked six hours after administration of anti-venom 
and, if still abnormal, a repeat dose is indicated 2. The clinician should keep in mind that coagulopathy 
is often associated with concurrent cyto- or neurotoxic envenoming. These patients should be 
resuscitated and managed as required for all the clinical sequelae of the bite. 
Anti-venom 
Anti-venom was first developed by Calmette in the late 19th century 2, 14. Immunoglobulins are extracted 
and purified, usually from animal serum after previous immunization to that specific venom. Anti-
venom can be mono- or polyspecific, depending on whether it is effective against a single or multiple 
species’ venom. Polyvalent anti-venom is usually created geographically to cater specifically for the 
most common bites in that particular region. The large variability in inter- and intra-species venom 
constitution makes development of anti-venom challenging. This is compounded by the requirement of 
having venom from all the particular species available to manufacturing companies. Economical and 
distribution difficulties result in anti-venom being unavailable to large populations that are at particular 
risk of snake bite.  
 
Anti-venom reactions are common, with more than 10% of patients developing a reaction. These vary 
from early Type I hypersensitivity reactions to late serum sickness type reactions. Hypersensitivity is 
due to the use of animal serum and patients with previous exposure to animal serum are at particular 
risk. The use of pre-administration sensitivity testing is inaccurate, wastes time in patients that are 
critically ill and should therefore be avoided 2. Anti-venom should always be administered, resources 
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permitting, with suitable monitoring and resuscitation equipment available. Intra-muscular adrenaline is 
the treatment of choice in patients with immediate reactions. Corticosteroids and anti-histamines are 
indicated as in other causes of anaphylaxis. Patients who receive anti-venom must be monitored for at 
least 2 hours post-administration.  
 
The lack of anti-venom availability and the risks of its administration must always be considered by the 
clinician treating a patient with snakebite. The majority of bite victims can be managed safely and 
successfully without anti-venom. Administration must, however, not be delayed in cases in which anti-
venom is indicated (Table 1). Clinicians must familiarise themselves with regional anti-venom 
availability and whom to contact to obtain these in case of a venomous bite. 
Conclusions 
 
Snake bite is a huge public health concern, mostly affecting those in rural areas in low and middle 
income countries with poor access to healthcare. This is further complicated by a lack of availability of 
anti-venom, and no good quality evidence base on how to manage bites most effectively. This paper 
helps to provide clinicians who might have to treat snake bite patients with information on the 
identification and management of the syndromic sequelae of snake bites, with or without the 
availability of anti-venom. It is essential that the evidence base for effective snake bite treatment is 
expanded in order to reduce the devastating public health impact of this neglected tropical disease. 
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